Skip to content

Lymphocytes Subpopulation in Cancer Patients

Lymphocytes Subpopulation and Its Relevance With Tumor Grade and Prognosis in Cancer Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02516371
Acronym
CaLym
Enrollment
100
Registered
2015-08-05
Start date
2015-08-31
Completion date
2018-12-31
Last updated
2015-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

This study aims to exam the subpopulation of lymphocytes and evaluate the clinico-pathologic correlations.

Detailed description

The host's inflammatory response in the tumor microenvironment could effect cancer progression and prognosis. As components of systemic inflammatory response, lymphocytes, neutrophils, and platelets are being recognised to have an important role in carcinogenesis and tumor progression. To date, a number of peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and so on have been proposed as prognostic markers in numerous types of cancers. But, very little is known of their impact in subpopulation of lymphocytes. The investigators try to evaluate the activity of lymphocytes in peripheral blood and find out the relationship among clinical prognosis.

Interventions

OTHERlymphocyte

To evaluate the subpopulation of lymphocytes in cancer patients

Sponsors

DERSHENG SUN
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. cancer patients of Uijeongbu St. Mary's Hospital 2. never treated with chemotherapy 3. Age between 20\ 80 years-

Exclusion criteria

1. treated with chemotherapy before 2. No informed consent form

Design outcomes

Primary

MeasureTime frame
response rate after cancer treatment with chemotherapy6 months after chemotherapy

Countries

South Korea

Contacts

Primary ContactYoon Ho Ko, MD, PhD
koyoonho@catholic.ac.kr82-31-820-3985
Backup ContactDer Sheng Sun, MD, PhD
ds-sun@hanmail.net82-31-820-3584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026